1346608-76-1

Basic information

• Product Name: 4-(3-Hydroxyoxetan-3-yl)benzoic acid
• Synonyms: 4-(3-Hydroxyoxetan-3-yl)benzoic acid
• CAS NO: 1346608-76-1
• Molecular Weight: 194.187
• Mol File: 1346608-76-1.mol

Chemical Properties

• CAS DataBase Reference: 4-(3-Hydroxyoxetan-3-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Hydroxyoxetan-3-yl)benzoic acid(1346608-76-1)
• EPA Substance Registry System: 4-(3-Hydroxyoxetan-3-yl)benzoic acid(1346608-76-1)

Safety Data

• Hazardous Substances Data: 1346608-76-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Hydroxyoxetan-3-yl)benzoic acid is used as a potential active pharmaceutical ingredient for its unique structure and potential biological activities, which may contribute to the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(3-Hydroxyoxetan-3-yl)benzoic acid serves as a valuable compound for the synthesis of novel molecules with potential therapeutic applications, given its distinctive structural features.
Used in Organic Synthesis:
4-(3-Hydroxyoxetan-3-yl)benzoic acid is utilized as a key intermediate in organic synthesis, enabling the creation of a variety of complex organic molecules for research and industrial applications.

Upstream product

• 6704-31-0 oxetan-3-one 
• 586-76-5 4-Bromobenzoic acid 
• 1085453-63-9 4-(3-hydroxyoxetan-3-yl)benzenecarbonitrile 

Relevant articles and documents

Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics

Non-alcoholic steatohepatitis (NASH) presents as an epidemic chronic liver disease that is closely associated with metabolic disorders and involves hepatic steatosis, inflammation, and fibrosis as key factors. Despite the enormous global prevalence of NASH, effective pharmacological interventions are lacking. Based on the hypothesis that the multifactorial condition NASH may benefit from combined multiple modes of action for enhanced therapeutic efficacy, we have previously developed dual FXR activators/sEH inhibitors (FXRa/sEHi) and observed remarkable antifibrotic effects upon their use in rodent NASH models. However, these first-generation FXRa/sEHi were characterized by moderate metabolic stability and short in vivo half-life. Aiming to overcome these pharmacokinetic drawbacks, we have systematically studied the structure-activity and structure-stability relationships of the chemotype and obtained second-generation FXRa/sEHi with improved pharmacokinetic parameters. With high plasma exposure, a half-life greater than 5 h, and similar dual potency on the intended targets, 13 presents as a substantially optimized FXRa/sEHi for late-stage preclinical development.

NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA

The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds

SUBSTITUTED BIPIPERIDINYL DERIVATIVES

The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.